Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | UPP1 | Q16831 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9820198 | 0.81 | ATM (1.00) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL1694758 | 0.81 | KDM4E (0.61) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL8471827 | 0.81 | KDM4E (1.00) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL16398184 | 0.81 | KDM4E (0.61) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL8901518 | 0.78 | UPP1 (0.61) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL5780522 | 0.78 | KDM4E (0.53) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL3794931 | 0.78 | KDM4E (0.64) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL10815675 | 0.77 | KDM4E (0.56) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL16334999 | 0.75 | POLB (0.58) | KDM4EATMALDH1A1UPP1HPGD | |
| SCHEMBL1086023 | 0.74 | UPP1 (0.53) | KDM4EATMALDH1A1UPP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190869-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2024-06-13 | — | — | US | disclosed |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210309659-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2021-10-07 | — | — | US | disclosed |
| CN-109641898-A | For treat nerve and neurodegenerative disease 5,7- dihydro-pyrrole simultaneously-pyridine derivate | 辉瑞公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20180002331-A1 | 5,7-Dihydro-Pyrrolo-Pyridine Derivatives | PFIZER INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| WO-2010117425-A1 | CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | BIOGEN IDEC MA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-0104876-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-12-27 | — | — | EP | disclosed |
| US-4631081-A | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1986-12-23 | — | — | US | disclosed |
| EP-0104876-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190869-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | KDM4E 900/4885ATM 2839/4885ALDH1A1 754/4885 |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | KDM4E 1401/4885ATM 703/4885ALDH1A1 1904/4885 |
| US-20210309659-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | KDM4E 900/4885ATM 2839/4885ALDH1A1 754/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | KDM4E 3648/4885ATM 4151/4885ALDH1A1 1070/4885 |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | KDM4E 900/4885ATM 2839/4885ALDH1A1 754/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | KDM4E 1401/4885ATM 703/4885ALDH1A1 1904/4885 |
| US-20180002331-A1 | 5,7-Dihydro-Pyrrolo-Pyridine Derivatives | CHRM1, CHRM5, CHRM2 | KDM4E 900/4885ATM 2839/4885ALDH1A1 754/4885 |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | CHRM1, CHRM5, CHRM2 | KDM4E 900/4885ATM 2839/4885ALDH1A1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.